MERCK KGAA SEEKS APPROVAL OF ERBITUX IN COMBINATION WITH RADIATION THERAPY

Merck KGaA said it has submitted an application to the European Medicines Agency (EMEA) and Swissmedic to extend the use of cancer drug Erbitux to treat head and neck cancer in combination with radiation therapy. It said Erbitux is to be used in combination with radiation for locally advanced squamous cell carcinoma of the head and neck and also as monotherapy in patients with recurrent or metastatic disease where prior chemotherapy has failed.

Forbes (http://www.forbes.com/business/feeds/afx/2005/08/30/afx2196153.html)